---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-013970"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:17:38.468053+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Telomir-1 inhibits KDM5 demethylase families in vitro, expanding epigenetic targeting

## Summary
- Telomir-1 inhibits KDM5A, KDM5B, and KDM5C in vitro, blocking silencing of tumor suppressor genes.
- Adds to prior activity on KDM2/KDM6 families and DNA methylation, unique among epigenetic therapies.
- Telomir-1 spared GCN5L2 acetyltransferase, indicating potential for reduced systemic toxicity.
- IND-enabling studies and GMP scale-up ongoing; additional preclinical evaluations in cancer and aging.

## SEC filing metadata
- accession: 0001493152-25-013970
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225013970/0001493152-25-013970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225013970/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-013970
- JSON: https://secwatch.observer/filing/0001493152-25-013970.json
- Plain text: https://secwatch.observer/filing/0001493152-25-013970.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.